Beyond imaging: Leveraging molecular tools to detect MRD for personalized cancer care

Dr. Alan Tan, MD, serves as an Associate Professor within the Division of Hematology, Oncology, and Cell Therapy at the esteemed Vanderbilt Ingram Cancer Center. He holds the distinguished position of Bladder Cancer Medical Oncology Research Lead, demonstrating his expertise in the field. Dr. Tan's professional focus extends to encompass Kidney Cancer, Prostate Cancer, and Melanoma.

With a clinical research emphasis, Dr. Tan is actively engaged in the design and execution of clinical trials aimed at evaluating innovative immunotherapies and targeted therapies for urothelial cancers, renal cell carcinoma, and other genitourinary malignancies. Furthermore, he demonstrates a keen interest in precision genomic cancer medicine, wherein he endeavors to identify molecular aberrations to facilitate the development of personalized treatment modalities.

Prior to his arrival at Vanderbilt, Dr. Tan held the position of Director of Genitourinary Oncology at Rush University Medical Center in Chicago, Illinois, further solidifying his standing as a leader in the field. His contributions are widely recognized through numerous publications and presentations at prominent oncology conferences.

Dr. Tan is an esteemed member of several professional organizations, including the American Society of Clinical Oncology (ASCO), the European Society for Medical Oncology (ESMO), the Society for Immunotherapy of Cancer (SITC), Bladder Cancer Advocacy Network (BCAN), Kidney Cancer Association (KCA), and the American Association for Cancer Research (AACR).

Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.

Dr. Cynthia Ma is Professor of Medicine within the Division of Oncology, Department of Medicine, at Washington University School of Medicine, in St. Louis, MO. She is a breast oncologist and a physician scientist, whose research focuses on endocrine therapy and targeted agents for the treatment of breast cancer. She has led several biomarker directed, investigator initiated trials including neoadjuvant studies of endocrine agents in combination with inhibitors against PI3K pathway or the CDK4/6 in patients with locally advanced estrogen receptor positive breast cancer. She is the study chair for the ongoing ALLIANCE ALTERNATE trial, which evaluates Ki67 based biomarkers as well as genomic predictors of endocrine responsiveness and a member of the Alliance Breast Committee. Dr. Ma is the clinical director of the Breast Cancer Program in Medical Oncology at Washington University School of Medicine; Co-leader of the Breast Cancer Focus Group and Breast Cancer Research Program at Siteman Cancer Center located in St. Louis, MO. She is a member of multiple scientific and research committees; Section Editor for Current Breast Cancer Report and serves as an Editorial Board Member on several major journals. Dr. Ma was recently elected as the Vice President of CAHON (Chinese American Hematologist and Oncologist Network).

Dr. Cohen is a leading medical oncologist and cancer researcher who brings a unique combination of extensive clinical and research experience to Tempus’ leadership team. He was most recently the Chief of the Division of Hematology-Oncology as well as the Associate Director of Clinical Science at UC San Diego (UCSD) Moores Cancer Center. Dr. Cohen also led the Precision Immunotherapy Clinic and co-directed the San Diego Center for Precision Immunotherapy at UCSD. Before UCSD, Dr. Cohen spent 15 years at the University of Chicago, where he was the co-director of the Head and Neck Cancer Program as well as Hematology/Oncology Fellowship Program Director.